Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

被引：16
|
作者：
Kaul, Sanjay [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, 8635 W Third St,Ste 790W, Los Angeles, CA 90048 USA
来源：
CIRCULATION | 2016年 / 134卷 / 02期
关键词：
clinical trial; diabetes mellitus; mortality; TRIAL;
D O I：
10.1161/CIRCULATIONAHA.116.022537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：94 / +
页数：11
相关论文
共 50 条
  • [1] Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus
    Jaeschke, Roman
    Gerstein, Hertzel
    [J]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 803 - 805
  • [2] Mortality benefit from unrestricted access to clopidogrel: Too good to be true?
    Suissa, Samy
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 178 (04) : 425 - 427
  • [3] Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus
    Zimmermann, Jay
    [J]. AMERICAN FAMILY PHYSICIAN, 2016, 94 (12) : 1014 - 1015
  • [4] Understanding the mechanisms mediating cardi-renal benefit of empagliflozin in type 2 diabetes mellitus
    Patoulias, Dimitrios
    Eid, Ali H.
    Rizzo, Manfredi
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (12)
  • [5] Stopping trials early for benefit: too good to be true
    不详
    [J]. LANCET, 2008, 371 (9621): : 1310 - 1310
  • [6] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 22 - 22
  • [7] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    [J]. JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 54 - 54
  • [8] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22): : 2117 - 2128
  • [9] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Fischereder, Michael
    Schoenermarck, Ulf
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1092 - 1093
  • [10] Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Yaribeygi, Habib
    Maleki, Mina
    Sathyapalan, Thozhukat
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    [J]. CURRENT MEDICINAL CHEMISTRY, 2023, 30 (25) : 2850 - 2863
12345